Wall Street analysts expect G1 Therapeutics Inc (NASDAQ:GTHX) to report ($0.97) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for G1 Therapeutics’ earnings. The highest EPS estimate is ($0.90) and the lowest is ($1.07). G1 Therapeutics reported earnings of ($0.65) per share in the same quarter last year, which indicates a negative year over year growth rate of 49.2%. The business is scheduled to report its next quarterly earnings report on Thursday, February 27th.
On average, analysts expect that G1 Therapeutics will report full-year earnings of ($3.29) per share for the current financial year, with EPS estimates ranging from ($3.39) to ($3.23). For the next financial year, analysts expect that the business will post earnings of ($4.43) per share, with EPS estimates ranging from ($5.34) to ($3.92). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for G1 Therapeutics.
Several research analysts have recently issued reports on GTHX shares. ValuEngine upgraded shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Monday. Zacks Investment Research cut shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 8th. BTIG Research raised their target price on shares of G1 Therapeutics from $51.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Needham & Company LLC reiterated a “buy” rating and issued a $74.00 price target on shares of G1 Therapeutics in a report on Thursday, December 12th. Finally, Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a report on Thursday, December 12th. Two research analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $61.43.
A number of large investors have recently added to or reduced their stakes in GTHX. Rhenman & Partners Asset Management AB boosted its holdings in G1 Therapeutics by 95.3% in the third quarter. Rhenman & Partners Asset Management AB now owns 535,657 shares of the company’s stock valued at $12,202,000 after acquiring an additional 261,383 shares in the last quarter. State Street Corp boosted its holdings in G1 Therapeutics by 19.8% in the fourth quarter. State Street Corp now owns 1,375,328 shares of the company’s stock valued at $36,350,000 after acquiring an additional 227,433 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in G1 Therapeutics in the second quarter valued at $3,505,000. Vanguard Group Inc. boosted its holdings in G1 Therapeutics by 5.4% in the second quarter. Vanguard Group Inc. now owns 1,976,615 shares of the company’s stock valued at $60,603,000 after acquiring an additional 100,523 shares in the last quarter. Finally, Redmile Group LLC boosted its holdings in G1 Therapeutics by 33.5% in the third quarter. Redmile Group LLC now owns 390,934 shares of the company’s stock valued at $8,905,000 after acquiring an additional 98,200 shares in the last quarter. Institutional investors and hedge funds own 76.68% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Recommended Story: Trading Stocks – What are percentage gainers?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.